Search

OBJECTIVE--To evaluate the efficacy and long-term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents. RESEARCH DESIGN AND METHODS--A total of 1,261 patients (HbA1c ≥7.0% [53 mmol/mol] to ≤10.0%[86 mmol/mol]) on basal insulin alone or combined with metformin and/ or pioglitazone were randomized (1:1) to double-blind treatment with linagliptin 5mg once daily or placebo for ≥52 weeks. The basal insulin dose was kept unchanged for 24 weeks but could thereafter be titrated according to fasting plasma glucose levels at the investigators' discretion. The primary end point was the mean change in HbA1c from baseline to week 24. The safety analysis incorporated data up to a maximum of 110 weeks. RESULTS--At week 24, HbA1c changed from a baseline of 8.3% (67 mmol/mol) by 20.6% (26.6 mmol/mol) and by 0.1%(1.1mmol/mol) with linagliptin and placebo, respectively (treatment difference 20.65% [95% CI 20.74 to 20.55] [-7.1 mmol/mol]; P<0.0001). Despite the option to uptitrate basal insulin, it was adjusted only slightly upward (week 52, linagliptin 2.6 IU/day, placebo 4.2 IU/day; P < 0.003), resulting in no further HbA1c improvements. Frequencies of hypoglycemia (week 24, linagliptin 22.0%, placebo 23.2%; treatment end, linagliptin 31.4%, placebo 32.9%) and adverse events (linagliptin 78.4%, placebo 81.4%) were similar between groups. Mean body weight remained unchanged (week 52, linagliptin 20.30 kg, placebo 20.04 kg). CONCLUSIONS--Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight. [ABSTRACT FROM AUTHOR]